Intra-cellular therapies reports third quarter 2023 financial results and raises 2023 caplyta sales guidance

Q3 2023 total revenues increased to $126.2 million , compared to $71.9 million in the same period in 2022
ITCI Ratings Summary
ITCI Quant Ranking